Floatz logo

CD16/IL15/CD33 TRISPECIFIC KILLER CELL ENGAGER

High-risk Myelodysplastic Syndromes

GT Biopharma, Inc.protein_peptidePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

315 Active assets in the High-risk Myelodysplastic Syndromes cohort.

Asset / SponsorPhaseRating
Fludarabine
Sawa Ito, MD
Phase 4BB
Anti-Thymoglobulin, Rabbit
Peking University First Hospital
Phase 2/3BB
Cytosin-Arabinosid
The First Affiliated Hospital of Soochow University
Phase 4BB
FILGRASTIM
City of Hope Medical Center
Phase 4BB
Daunorubicin
OHSU Knight Cancer Institute
Phase 3BB

View all 50 →

Same molecule, other indications

CD16/IL15/CD33 TRISPECIFIC KILLER CELL ENGAGER is also rated in:

systemic mastocytosisDormant
CCC
Indicative ·
48 / 100
View asset →
mast cell leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →